Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 21, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/21/17 - "Method for Preparing Palbociclib" in Patent Application Approval Process (USPTO 20170247379)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventor XU, Xuenong, filed on May 15, 2017, was made available online on September 7, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The following quote was obtained by the news editors from the background inf
9/21/17 - 60 Degrees Pharmaceuticals, Washington, Assigned Patent for Dosing Regimens of Celgosivir for Treatment of Dengue
60 Degrees Pharmaceuticals, Washington, Singapore Health Services, Singapore, and National University of Singapore, Singapore, have been assigned a patent developed by nine co-inventors for "dosing regimens of celgosivir for the treatment of dengue." The co-inventors are Geoffrey S. Dow, Washington, Subhash Vasudevan, Singapore, Mark Reid, Toowong,
9/21/17 - Acceleron Announces Pricing of Public Offering of Common Stock
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public offering of 5,405,406 shares of common stock at a price to the public of $37.00 per shar
9/21/17 - Acceleron takes back drug rights from Celgene to start pulmonary push [Arab News (Saudi Arabia)]
Acceleron`s long-running collaboration with Celgene on sotatercept has taken another turn today, with an amendment of their agreement to give Acceleron the right to develop the drug for pulmonary diseases. The biopharma`s CEO Habib Dable told analysts that PAH has a high unmet need, with around 30,000 patients in the U.S. alone and no disease-modif
9/21/17 - Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York [Emirates News Agency (WAM) (United Arab Emirates)]
-Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Aclaris will host an R&D and Investor Event on Wednesday, October 4, 2017, in New Yor
9/21/17 - Africa to get state-of-art HIV drugs for Sh7,000 a year [Business Daily (Kenya)]
PHOTO| FILE Makers of generic AIDS drugs will start churning out millions of pills for Africa containing a state-of-the-art medicine widely used in rich countries, after securing a multi-million dollar guarantee that caps prices at just $75 per patient a year. The agreement, which will make the treatment available to 92 poor countries, starting in
9/21/17 - Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
Akari Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, announces that, following advice from a recent FDA Type B End of Phase II Meeting, it plans to advance its lead investigational drug, Coversin?, towards Phase III clini
9/21/17 - Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that results from a clinical phase I study of the drug candidate ADC-1013 will be presented at the Society for Immunotherapy of Cancer 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National..
9/21/17 - Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar [Tehran Times (Iran)]
The big Cambridge, MA- based biotech says that their Phase III study of patisiran partnered with Sanofi scored a positive hit for the primary as well as all secondary endpoints in treating rare cases of hereditary ATTR amyloidosis with polyneuropathy. The score sets up Alnylams first new drug application with the FDA before the end of this year wit
9/21/17 - AMICUS THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 21, 2017, Amicus Therapeutics, Inc. issued a press release announcing that the U.S. FDA granted Orphan Drug Designation for ATB200/AT2221 for Pompe Disease. A copy of this press release is attached hereto as Exhibit 99.1. Description 99.1 Press Release dated September 21, 2017 titled " U.S. FDA Grants Orphan Drug Designation for ATB200
9/21/17 - AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other EventsItem 8.01. Other Events. On September21, 2017, Amicus Therapeutics,Inc. (the Company) issued a press release announcing that the U.S. FDA granted Orphan Drug Designation for ATB200/AT2221 for Pompe Disease. A copy of this press release is attached hereto as Exhibit99.1. Item 9.01
9/21/17 - Ammonett Pharma, Midlothian, Va., Assigned Patent for Treating Growth Hormone Deficiency
Ammonett Pharma, Midlothian, Virginia, has been assigned a patent developed by Michael Oliver Thorner, Charlottesville, Virginia, for "detecting and treating growth hormone deficiency." The patent application was filed on Sept. 21, 2016. Written by Kusum Sangma; edited by Sudarshan Harpal.
9/21/17 - Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017
Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that seven posters from the APX001 development program will be presented at the Infectious Diseases Society of America IDWeek 2017, being held in San Diego, CA, from October 4 to 8, 2017. 1513. Absorption,.
9/21/17 - Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer s disease, other central nervous system diseases, pain and various types of cancer, will present at the Ladenburg Thalmann 2017 Healthcare...
9/21/17 - ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a corporate overview at the Sidoti& Company Fall 2017 Conference, taking place September 28, 2017 in New York, New York. ARCA biopharma is dedicated
9/21/17 - argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia [Sport360]
Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has recruited 50% of the immune thrombocytopenia patients in the Phase 2 proof-of-concept study of ARGX-113.
9/21/17 - Around Danvers
Blood donation opportunity: 12:45 -6: 15 p.m. Sept. 21 and 25-28; 8:30 a.m. -2 p.m. Sept. 22-24, 29 and 30, Danvers Blood Donation Center, 99 Rosewood Drive. Concerned Citizens- MassDot Project #607954 meeting: 7 p.m. Sept. 21, Peabody City Hall, floor two, 24 Lowell St., Peabody. Concerned Citizens of Peabody has invited the community to a meeting
9/21/17 - Assured Bites, Inc. Petition Approval Marks First-Ever FDA Qualified Health Claim Linking Early Peanut Introduction to Allergy Prevention
By a News Reporter-Staff News Editor at Politics& Government Business Assured Bites, Inc., a New York- based family health and wellness company on the forefront of peanut allergy prevention, is pleased to announce the U.S Food and Drug Administration has approved its petition for a qualified health claim linking early peanut introduction and the
9/21/17 - AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease
AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO s third gene therapy for Lysosomal Storage Disorders, following on the heels of the Company s Phase 1 Fabry p
9/21/17 - Bavarian Nordic Provides Update on its Universal RSV Vaccine
*Preliminary 6 Month Phase 2 Data continue to Demonstrate a Broad and Durable Immune Response against RSV* Updated Clinical Plans to Develop and Initiate a Human Challenge Study in 2018 COPENHAGEN, Denmark, September 21, 2017- Bavarian Nordic A/S today announced initial 6 month follow-up data from the Phase 2 trial of MVA-BN RSV, a universal vaccin
9/21/17 - Bharat Book Bureau: Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024
United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. *Sanofi to Acquire Protein Sciences Corporation. "Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024" provides a deep and thorough evaluation of the United States flu vaccine market.
9/21/17 - BioCryst's RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication
BioCryst Pharmaceuticals, Inc. a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for RAPIVAB, an intravenous neuraminidase inhibitor, extending its availability for the.
9/21/17 - BioPharma Institute Launches 5 Top U.S. Pharmaceutical & Clinical Research Industry Regulatory Compliance Courses as Parent Company Celebrates 20th Anniversary
Today, BioPharma Institute, a leading training platform for highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of 5 new courses to its prospectus. Providing many world-class training programs and courses, the BioPharma Institute is trusted by thousands of highly skilled biopharmaceutical industry.
9/21/17 - Brainlab announces FDA clearance for two new indication-specific radiosurgery software applications
Brainlab announced today that it has received FDA clearance for Elements Spine SRS and Elements Cranial SRS, two software applications that aid in the patient-tailored planning of radiosurgery treatments for indications of the spine and brain. With FDA clearance of these software modules, the Brainlab Elements portfolio of applications that facilit
9/21/17 - Brammer ups early phase manufacturing capacity [Arab Times (Kuwait)]
The cell and gene therapy contract development and manufacturing organization has completed its clinical capacity expansion in Alachua, Florida. In May of this year, the company also invested in its commercial-scale gene therapy manufacturing facility in Cambridge, MA. The facility is slated to open in the second half of the year. The company curre
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement